Isis will hold a conference call and live audio webcast today, December 11, 2012 at 8:30 am ET to provide detailed information on its new strategic alliance with AstraZeneca. Interested parties may listen to the call by dialing 866-713-8567and refer to passcode "ISIS 2012," or access the webcast at www.isispharm.com.
ABOUT ISIS-STAT3 Rx
is the first drug in Isis' pipeline that incorporates Isis' Generation 2.5 chemistry, which was developed to increase potency of antisense drugs thereby creating opportunities for drugs like ISIS-STAT3
to be more effective in addressing targets in a broader range of tissues, including tumors. ISIS-STAT3
is designed to inhibit the production of signal transducer and activator of transcription 3 (STAT3), a protein critical for tumor growth and survival. Because STAT3 is overexpressed in numerous types of cancers, ISIS-STAT3
has the potential to be broadly useful for both solid and hematological tumors. Isis recently reported encouraging data from its ongoing Phase 1 study showing that ISIS-STAT3
had an acceptable safety profile and treatment with ISIS-STAT3
resulted in clear responses in a number of patients with advanced cancer who were refractory to multiple prior chemotherapy treatments. The indication of activity so early in development in a Phase 1 study prompted Isis to initiate a follow up clinical study to evaluate the safety and efficacy of ISIS-STAT3
in focused patient populations with lymphomas and other advanced hematologic cancers linked to activation of STAT3 who have failed other treatment options.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in
the United States
following regulatory approval. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements, including statements regarding Isis' strategic alliance with AstraZeneca, Isis' research and development opportunities in cancer, the development, activity, therapeutic potential and safety of ISIS-STAT3
, and the therapeutic benefit of antisense drugs that incorporate Isis' Generation 2.5 chemistry. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended
December 31, 2011
and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO™ is a trademark of Genzyme Corporation.